We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tosoh Bioscience Introduces HPLC Column

Tosoh Bioscience Introduces HPLC Column  content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Tosoh Bioscience LLC, a provider of chromatographic solutions for the separation of biomolecules, has announced the introduction of its TSKgel FcR-IIIA-5PW HPLC column. This column is the second in the FcRγ affinity chromatography portfolio for antibody drug analysis developed independently by Tosoh Corporation.

The TSKgel FcR-IIIA-5PW is a semi-preparative affinity column based on a recombinant FcγRIIIA receptor ligand bonded to porous 10 µm polymethacrylate particles. The column can be loaded with up to 5 mg of monoclonal antibody (mAb), allowing material collection in sufficient quantity for in-depth analysis.

Both TSKgel FcR-IIIA columns, the FcR-IIIA-5PW and FcR-IIIA-NPR, separate antibodies based on the affinity of their Fc region for a particular Fc receptor (FcγIIIa) into three fractions. These fractions correlate with different mAb glycoforms and their antibody-dependent cellular cytotoxicity (ADCC) activity. Thus the columns represent a tool to rapidly link FcγIIIa receptor affinity with mAb function and structure. Characterizing each of the fractions with orthogonal methods allows for linking FcγIIIa receptor affinity to structural causes and functional effects. For this purpose, a workflow was established to determine the glycosylation pattern in different affinity fractions with HILIC-MS.